[
Contrast media
Lymphoma
Magnetic resonance imaging
Neoplasm staging
Positron-emission tomography
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
27
12
2022
accepted:
14
04
2023
revised:
07
03
2023
medline:
27
10
2023
pubmed:
20
6
2023
entrez:
20
6
2023
Statut:
ppublish
Résumé
Evaluate the influence of an MRI contrast agent application on primary and follow-up staging in pediatric patients with newly diagnosed lymphoma using [ A total of 105 [ In patient-based analysis, PET/MRI-1 and PET/MRI-2 both determined a correct IPNHLSS tumor stage in 90/105 (86%) exams. Region-based analysis correctly identified 119/127 (94%) lymphoma-affected regions. Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy for PET/MRI-1 and PET/MRI-2 were 94%, 97%, 90%, 99%, 97%, respectively. There were no significant differences between PET/MRI-1 and PET/MRI-2. The use of MRI contrast agents in [ This study gives a scientific baseline switching to a contrast agent-free [ • No additional diagnostic benefit of MRI contrast agents at [
Identifiants
pubmed: 37338559
doi: 10.1007/s00330-023-09840-5
pii: 10.1007/s00330-023-09840-5
pmc: PMC10598113
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Contrast Media
0
Radiopharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8366-8375Informations de copyright
© 2023. The Author(s).
Références
Steliarova-Foucher E, Fidler MM, Colombet M et al (2018) Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991–2010 (Automated Childhood Cancer Information System): a population-based study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(18)30423-6
doi: 10.1016/S1470-2045(18)30423-6
pubmed: 30098952
pmcid: 6120055
Linet MS, Ries LA, Smith MA, Tarone RE, Devesa SS (1999) Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst. https://doi.org/10.1093/jnci/91.12.1051
doi: 10.1093/jnci/91.12.1051
pubmed: 10580037
Lin C, Itti E, Haioun C et al (2007) Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. https://doi.org/10.2967/jnumed.107.042093
doi: 10.2967/jnumed.107.042093
pubmed: 18006616
El-Galaly TC, Hutchings M (2015) Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies. Cancer Treat Res. https://doi.org/10.1007/978-3-319-13150-4_5
doi: 10.1007/978-3-319-13150-4_5
pubmed: 25655608
Barrington SF, Mikhaeel NG, Kostakoglu L et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. https://doi.org/10.1200/jco.2013.53.5229
Wen JC, Sai V, Straatsma BR, McCannel TA (2013) Radiation-related cancer risk associated with surveillance imaging for metastasis from choroidal melanoma. JAMA Ophthalmol. https://doi.org/10.1001/jamaophthalmol.2013.564
doi: 10.1001/jamaophthalmol.2013.564
pubmed: 24030343
pmcid: 4111937
Brenner DJ, Elliston CD (2004) Estimated radiation risks potentially associated with full-body CT screening. Radiology. https://doi.org/10.1148/radiol.2323031095
doi: 10.1148/radiol.2323031095
pubmed: 15273333
Brix G, Nosske D, Lechel U (2014) Radiation exposure of patients undergoing whole-body FDG-PET/CT examinations: an update pursuant to the new ICRP recommendations. Nuklearmedizin. https://doi.org/10.3413/Nukmed-0663-14-04
doi: 10.3413/Nukmed-0663-14-04
pubmed: 24919708
Schäfer JF, Gatidis S, Schmidt H et al (2014) Simultaneous whole-body PET/MR imaging in comparison to PET/CT in pediatric oncology: initial results. Radiology. https://doi.org/10.1148/radiol.14131732
doi: 10.1148/radiol.14131732
pubmed: 24877983
Heacock L, Weissbrot J, Raad R et al (2015) PET/MRI for the evaluation of patients with lymphoma: initial observations. AJR Am J Roentgenol. https://doi.org/10.2214/AJR.14.13181
Afaq A, Fraioli F, Sidhu H et al (2017) Comparison of PET/MRI with PET/CT in the evaluation of disease status in lymphoma. Clin Nucl Med. https://doi.org/10.1097/rlu.0000000000001344
doi: 10.1097/rlu.0000000000001344
pubmed: 27607161
pmcid: 5538384
Sher AC, Seghers V, Paldino MJ et al (2016) Assessment of sequential PET/MRI in comparison with PET/CT of pediatric lymphoma: a prospective study. AJR Am J Roentgenol. https://doi.org/10.2214/AJR.15.15083
Kirchner J, Deuschl C, Schweiger B et al (2017) Imaging children suffering from lymphoma: an evaluation of different 18F-FDG PET/MRI protocols compared to whole-body DW-MRI. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-017-3726-0
doi: 10.1007/s00259-017-3726-0
pubmed: 29282517
Picardi M, Cavaliere C, Della Pepa R et al (2021) PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial. Ann Hematol. https://doi.org/10.1007/s00277-021-04537-5
doi: 10.1007/s00277-021-04537-5
pubmed: 33909101
pmcid: 8116299
Platzek I, Beuthien-Baumann B, Langner J et al (2013) PET/MR for therapy response evaluation in malignant lymphoma: initial experience. MAGMA. https://doi.org/10.1007/s10334-012-0342-7
doi: 10.1007/s10334-012-0342-7
pubmed: 23086288
Drzezga A, Souvatzoglou M, Eiber M et al (2012) First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med. https://doi.org/10.2967/jnumed.111.098608
doi: 10.2967/jnumed.111.098608
pubmed: 23143086
Heusch P, Nensa F, Schaarschmidt B et al (2015) Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-014-2885-5
doi: 10.1007/s00259-014-2885-5
pubmed: 26243264
Sherief LM, Elsafy UR, Abdelkhalek ER et al (2015) Hodgkin lymphoma in childhood: clinicopathological features and therapy outcome at 2 centers from a developing country. Medicine (Baltimore). https://doi.org/10.1097/md.0000000000000670
doi: 10.1097/md.0000000000000670
pubmed: 26705211
Burkhardt B, Zimmermann M, Oschlies I et al (2005) The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. https://doi.org/10.1111/j.1365-2141.2005.05735.x
doi: 10.1111/j.1365-2141.2005.05735.x
pubmed: 16173961
Sorge I, Georgi TW, Hirsch FW (2021) Lymphomerkrankungen im Kindes- und Jugendalter. Radiologe. https://doi.org/10.1007/s00117-021-00873-9
doi: 10.1007/s00117-021-00873-9
pubmed: 34160645
Gatidis S, Schmidt H, Gücke B et al (2016) Comprehensive oncologic imaging in infants and preschool children with substantially reduced radiation exposure using combined simultaneous
doi: 10.1097/rli.0000000000000200
pubmed: 27272542
Doniselli FM, Albano D, Chianca V, Cimmino MA, Sconfienza LM (2017) Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: what rheumatologists should know. Clin Rheumatol. https://doi.org/10.1007/s10067-017-3604-y
doi: 10.1007/s10067-017-3604-y
pubmed: 28321569
Stanescu AL, Shaw DW, Murata N et al (2020) Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmation. Pediatr Radiol. https://doi.org/10.1007/s00247-019-04535-w
doi: 10.1007/s00247-019-04535-w
pubmed: 32681235
pmcid: 7340753
Raczeck P, Fries P, Bücker A, Schneider G (2019) Gadolinium deposition-“gadolinium deposition disease.” Radiologe. https://doi.org/10.1007/s00117-019-0522-9
doi: 10.1007/s00117-019-0522-9
pubmed: 30963195
Schneider GK, Stroeder J, Roditi G et al (2017) T1 Signal measurements in pediatric brain: findings after multiple exposures to gadobenate dimeglumine for imaging of nonneurologic disease. AJNR Am J Neuroradiol. https://doi.org/10.3174/ajnr.A5270
doi: 10.3174/ajnr.A5270
pubmed: 28642266
pmcid: 7963691
Arendt CT, Beeres M, Leithner D et al (2019) Gadolinium-enhanced imaging of pediatric thoracic lymphoma: is intravenous contrast really necessary? Eur Radiol. https://doi.org/10.1007/s00330-018-5859-3
doi: 10.1007/s00330-018-5859-3
pubmed: 30547199
Littooij AS, Kwee TC, Barber I et al (2016) Accuracy of whole-body MRI in the assessment of splenic involvement in lymphoma. Acta Radiol. https://doi.org/10.1177/0284185115571657
doi: 10.1177/0284185115571657
pubmed: 25681490
Albano D, Micci G, Patti C et al (2021) Whole-body magnetic resonance imaging: current role in patients with lymphoma. Diagnostics (Basel). https://doi.org/10.3390/diagnostics11061007
doi: 10.3390/diagnostics11061007
pubmed: 34943426
Georgi TW, Stoevesandt D, Kurch L et al (2022) Optimized whole-body positron emission tomography magnetic resonance imaging sequence workflow in pediatric Hodgkin lymphoma patients. J Nucl Med. https://doi.org/10.2967/jnumed.122.264112
doi: 10.2967/jnumed.122.264112
pubmed: 35835583
Co C, Health A (1988) Age limits of pediatrics. Pediatrics. https://doi.org/10.1542/peds.81.5.736
doi: 10.1542/peds.81.5.736
Ghielmini M, Vitolo U, Kimby E et al (2013) ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. https://doi.org/10.1093/annonc/mds517
doi: 10.1093/annonc/mds517
pubmed: 23175624
Eichenauer DA, Engert A, Andre M et al (2014) Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. https://doi.org/10.1093/annonc/mdu181
doi: 10.1093/annonc/mdu181
pubmed: 25185243
Quick HH (2014) Integrated PET/MR. J Magn Reson Imaging. https://doi.org/10.1002/jmri.24523
doi: 10.1002/jmri.24523
pubmed: 25430957
Rosolen A, Perkins SL, Pinkerton CR et al (2015) Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol. https://doi.org/10.1200/jco.2014.59.7203
doi: 10.1200/jco.2014.59.7203
pubmed: 26304908
pmcid: 4979194
Herrmann K, Queiroz M, Huellner MW et al (2015) Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT. BMC Cancer. https://doi.org/10.1186/s12885-015-2009-z
doi: 10.1186/s12885-015-2009-z
pubmed: 26699124
pmcid: 4690292
Grueneisen J, Sawicki L, Schaarschmidt B et al (2016) Evaluation of a fast protocol for staging lymphoma patients with integrated PET/MRI. PLoS One. https://doi.org/10.1371/journal.pone.0157880
Johnson SA, Kumar A, Matasar MJ, Schöder H, Rademaker J (2015) Imaging for staging and response assessment in lymphoma. Radiology. https://doi.org/10.1148/radiol.2015142088
doi: 10.1148/radiol.2015142088
pubmed: 26523493
Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C (2009) Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. https://doi.org/10.1080/10428190903040048
doi: 10.1080/10428190903040048
pubmed: 19883305
Flerlage JE, Hiniker SM, Armenian S et al (2021) Pediatric Hodgkin lymphoma, version 3.2021. J Natl Compr Cancer Netw. https://doi.org/10.6004/jnccn.2021.0027
(2017) Non-Hodgkin-Lymphome im Kindesalter. AWMF-Leitlinie. AWMF-Reg.-Nr. 025/013
(2018) LL Hodgkin-Lymphom. AWMF-Leitlinie 025/012
Sawicki LM, Grueneisen J, Schaarschmidt BM et al (2016) Evaluation of 18F-FDG PET/MRI, 18F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer. Eur J Radiol. https://doi.org/10.1016/j.ejrad.2015.12.010
doi: 10.1016/j.ejrad.2015.12.010
pubmed: 27776644
Buchbender C, Hartung-Knemeyer V, Beiderwellen K et al (2013) Diffusion-weighted imaging as part of hybrid PET/MRI protocols for whole-body cancer staging: does it benefit lesion detection? Eur J Radiol. https://doi.org/10.1016/j.ejrad.2013.01.019
doi: 10.1016/j.ejrad.2013.01.019
pubmed: 24011443
Ferdová E, Ferda J, Baxa J (2017) (18)F-FDG-PET/MRI in lymphoma patients. Eur J Radiol. https://doi.org/10.1016/j.ejrad.2017.01.023
doi: 10.1016/j.ejrad.2017.01.023
pubmed: 28283219
Martin O, Schaarschmidt BM, Kirchner J et al (2019) PET/MRI versus PET/CT in whole-body staging: results from a unicenter observational study in 1003 subsequent examinations. J Nucl Med. https://doi.org/10.2967/jnumed.119.233940
doi: 10.2967/jnumed.119.233940
pubmed: 31806777
pmcid: 6604688
Nougaret S, Nikolovski I, Paroder V et al (2019) MRI of tumors and tumor mimics in the female pelvis: anatomic pelvic space–based approach. Radiographics. https://doi.org/10.1148/rg.2019180173
doi: 10.1148/rg.2019180173
pubmed: 31283453
Corines MJ, Nougaret S, Weiser MR, Khan M, Gollub MJ (2018) Gadolinium-based contrast agent during pelvic MRI: contribution to patient management in rectal cancer. Dis Colon Rectum. https://doi.org/10.1097/dcr.0000000000000925
doi: 10.1097/dcr.0000000000000925
pubmed: 29337774
pmcid: 5772900
Welle CL, Guglielmo FF, Venkatesh SK (2020) MRI of the liver: choosing the right contrast agent. Abdom Radiol (NY). https://doi.org/10.1007/s00261-019-02162-5
Uslu L, Donig J, Link M, Rosenberg J, Quon A, Daldrup-Link HE (2015) Value of 18F-FDG PET and PET/CT for evaluation of pediatric malignancies. J Nucl Med. https://doi.org/10.2967/jnumed.114.146290
doi: 10.2967/jnumed.114.146290
pubmed: 25572088
Rizvi I, Zaman S, Zaidi N et al (2012) Superior vena cava syndrome caused by Hodgkin’s lymphoma in an adolescent girl. BMJ Case Rep. https://doi.org/10.1136/bcr.01.2012.5487
doi: 10.1136/bcr.01.2012.5487
pubmed: 23076704
pmcid: 4543847
Schönning A, Karlén J, Frisk T et al (2017) Venous thrombosis in children and adolescents with Hodgkin lymphoma in Sweden. Thromb Res. https://doi.org/10.1016/j.thromres.2017.02.011
doi: 10.1016/j.thromres.2017.02.011
pubmed: 28249199
Albano D, Patti C, Lagalla R, Midiri M, Galia M (2017) Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma. J Magn Reson Imaging. https://doi.org/10.1002/jmri.25439
doi: 10.1002/jmri.25439
pubmed: 28755383
Adams HJ, Kwee TC, Vermoolen MA et al (2013) Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET. Eur Radiol. https://doi.org/10.1007/s00330-013-2835-9
doi: 10.1007/s00330-013-2835-9
pubmed: 23591618
Agrawal K, Mittal BR, Bansal D et al (2013) Role of F-18 FDG PET/CT in assessing bone marrow involvement in pediatric Hodgkin’s lymphoma. Ann Nucl Med. https://doi.org/10.1007/s12149-012-0665-5
doi: 10.1007/s12149-012-0665-5
pubmed: 23143537
Cheng G, Chen W, Chamroonrat W, Torigian DA, Zhuang H, Alavi A (2011) Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-011-1815-z
doi: 10.1007/s00259-011-1815-z
pubmed: 21761266
pmcid: 4154802
Adams HJA, Kwee TC, de Keizer B et al (2014) Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary? Ann Oncol. https://doi.org/10.1093/annonc/mdt533
doi: 10.1093/annonc/mdt533
pubmed: 25214542
pmcid: 6267863
Adams HJA, de Klerk JMH, Fijnheer R et al (2016) Variety in bone marrow 18F-FDG uptake in Hodgkin lymphoma patients without lymphomatous bone marrow involvement: does it have an explanation? Nucl Med Commun. https://doi.org/10.1097/mnm.0000000000000400
doi: 10.1097/mnm.0000000000000400
pubmed: 27501435
Fan C, Hernandez-Pampaloni M, Houseni M et al (2007) Age-related changes in the metabolic activity and distribution of the red marrow as demonstrated by 2-deoxy-2-[F-18]fluoro-d-glucose-positron emission tomography. Mol Imag Biol. https://doi.org/10.1007/s11307-007-0100-9
doi: 10.1007/s11307-007-0100-9
Giraudo C, Raderer M, Karanikas G et al (2016) 18F-Fluorodeoxyglucose positron emission tomography/magnetic resonance in lymphoma: comparison with 18F-fluorodeoxyglucose positron emission tomography/computed tomography and with the addition of magnetic resonance diffusion-weighted imaging. Invest Radiol. https://doi.org/10.1097/rli.0000000000000218
doi: 10.1097/rli.0000000000000218
pubmed: 26784400
pmcid: 4747979
Radbruch A, Weberling LD, Kieslich PJ et al (2015) Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology. https://doi.org/10.1148/radiol.2015150337
doi: 10.1148/radiol.2015150337
pubmed: 26579564
Schaefer JF, Berthold LD, Hahn G et al (2019) Whole-body MRI in children and adolescents - S1 Guideline. Rofo. https://doi.org/10.1055/a-0832-2498
doi: 10.1055/a-0832-2498
pubmed: 31344721
Grueneisen J, Schaarschmidt B, Heubner M et al (2015) Implementation of FAST-PET/MRI for whole-body staging of female patients with recurrent pelvic malignancies: a comparison to PET/CT. Eur J Radiol. https://doi.org/10.1016/j.ejrad.2015.08.010
doi: 10.1016/j.ejrad.2015.08.010
pubmed: 26781152
Lindemann ME, Stebner V, Tschischka A, Kirchner J, Umutlu L, Quick HH (2018) Towards fast whole-body PET/MR: investigation of PET image quality versus reduced PET acquisition times. PLoS One. https://doi.org/10.1371/journal.pone.0206573
Kharuzhyk S, Zhavrid E, Dziuban A, Sukolinskaja E, Kalenik O (2020) Comparison of whole-body MRI with diffusion-weighted imaging and PET/CT in lymphoma staging. Eur Radiol. https://doi.org/10.1007/s00330-020-06732-w
doi: 10.1007/s00330-020-06732-w
pubmed: 32103366
Spijkers S, Littooij AS, Kwee TC et al (2021) Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study. Eur Radiol. https://doi.org/10.1007/s00330-020-07182-0
doi: 10.1007/s00330-020-07182-0
pubmed: 34021390
pmcid: 8589741
Shapira-Zaltsberg G, Wilson N, Trejo Perez E et al (2020) Whole-body diffusion-weighted MRI compared to (18 F)FDG PET/CT in initial staging and therapy response assessment of Hodgkin lymphoma in pediatric patients. Can Assoc Radiol J. https://doi.org/10.1177/0846537119888380
doi: 10.1177/0846537119888380
pubmed: 32062992
Hartung-Knemeyer V, Beiderwellen KJ, Buchbender C et al (2013) Optimizing positron emission tomography image acquisition protocols in integrated positron emission tomography/magnetic resonance imaging. Invest Radiol. https://doi.org/10.1097/RLI.0b013e3182823695
doi: 10.1097/RLI.0b013e3182823695
pubmed: 23493121